食管癌新辅助免疫疗法进展综述：分子生物标记物与未来方向

IF 5.7 2区医学 Q1 ONCOLOGY

International Journal of Cancer Pub Date : 2024-09-14 DOI:10.1002/ijc.35153

Wenjing Wang, Lisha Ye, Huihui Li, Wei Chen, Wei Hong, Weimin Mao, Xiaoling Xu

{"title":"食管癌新辅助免疫疗法进展综述：分子生物标记物与未来方向","authors":"Wenjing Wang, Lisha Ye, Huihui Li, Wei Chen, Wei Hong, Weimin Mao, Xiaoling Xu","doi":"10.1002/ijc.35153","DOIUrl":null,"url":null,"abstract":"<p>Esophageal cancer has a poor prognosis and survival rate due to its high incidence in Asia, lack of early symptoms and limited treatment options. In recent years, many clinical trials have demonstrated that immunotherapy has greatly improved the survival of patients with esophageal cancer. In addition, the combination of neoadjuvant immunotherapy with other popular therapeutic regimens has shown good efficacy and safety. In this review, we summarize the progress of clinical trials and some breakthroughs in neoadjuvant immunotherapy for esophageal cancer in recent years and suggest the possibility of multimodal neoadjuvant immunotherapy regimens, as well as directions for future development.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 1","pages":"20-33"},"PeriodicalIF":5.7000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions\",\"authors\":\"Wenjing Wang, Lisha Ye, Huihui Li, Wei Chen, Wei Hong, Weimin Mao, Xiaoling Xu\",\"doi\":\"10.1002/ijc.35153\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Esophageal cancer has a poor prognosis and survival rate due to its high incidence in Asia, lack of early symptoms and limited treatment options. In recent years, many clinical trials have demonstrated that immunotherapy has greatly improved the survival of patients with esophageal cancer. In addition, the combination of neoadjuvant immunotherapy with other popular therapeutic regimens has shown good efficacy and safety. In this review, we summarize the progress of clinical trials and some breakthroughs in neoadjuvant immunotherapy for esophageal cancer in recent years and suggest the possibility of multimodal neoadjuvant immunotherapy regimens, as well as directions for future development.</p>\",\"PeriodicalId\":180,\"journal\":{\"name\":\"International Journal of Cancer\",\"volume\":\"156 1\",\"pages\":\"20-33\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ijc.35153\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.35153","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

食道癌在亚洲发病率高，缺乏早期症状，治疗方法有限，因此预后和生存率较差。近年来，许多临床试验表明，免疫疗法大大提高了食管癌患者的生存率。此外，新辅助免疫疗法与其他常用治疗方案的结合也显示出良好的疗效和安全性。在这篇综述中，我们总结了近年来食管癌新辅助免疫治疗的临床试验进展和一些突破性进展，并提出了多模式新辅助免疫治疗方案的可能性以及未来的发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions

查看原文本刊更多论文

A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions

Esophageal cancer has a poor prognosis and survival rate due to its high incidence in Asia, lack of early symptoms and limited treatment options. In recent years, many clinical trials have demonstrated that immunotherapy has greatly improved the survival of patients with esophageal cancer. In addition, the combination of neoadjuvant immunotherapy with other popular therapeutic regimens has shown good efficacy and safety. In this review, we summarize the progress of clinical trials and some breakthroughs in neoadjuvant immunotherapy for esophageal cancer in recent years and suggest the possibility of multimodal neoadjuvant immunotherapy regimens, as well as directions for future development.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Cancer 医学-肿瘤学

CiteScore

13.40

自引率

3.10%

发文量

460

审稿时长

2 months

期刊介绍： The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories: -Cancer Epidemiology- Cancer Genetics and Epigenetics- Infectious Causes of Cancer- Innovative Tools and Methods- Molecular Cancer Biology- Tumor Immunology and Microenvironment- Tumor Markers and Signatures- Cancer Therapy and Prevention